Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 2/2014

Open Access 01-04-2014 | Research

Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials

Authors: Shanmiao Gou, Zhiyong Yang, Tao Liu, Heshui Wu, Chunyou Wang

Published in: Critical Care | Issue 2/2014

Login to get access

Abstract

Introduction

Necrotic tissue infection can worsen the prognosis of severe acute pancreatitis (SAP), and probiotics have been shown to be beneficial in reducing the infection rate in animal experiments and primary clinical trials. However, the results of multicenter randomized clinical trials have been contradictory. Our aim in this study was to systematically review and quantitatively analyze all randomized controlled trials with regard to important outcomes in patients with predicted SAP who received probiotics.

Methods

A systematic literature search of the PubMed, Embase and Cochrane Library databases was conducted using specific search terms. Eligible studies were randomized controlled trials that compared the effects of probiotic with placebo treatment in patients with predicted SAP. Mean difference (MD), risk ratio (RR) and 95% confidence interval (95% CI) were calculated using the Mantel-Haenszel fixed- and random-effects models. A meta-analysis on the use of probiotics in the treatment of critically ill patients was also performed to serve as a reference.

Results

In this study, 6 trials comprising an aggregate total of 536 patients were analyzed. Significant heterogeneities were observed in the type, dose, treatment duration and clinical effects of probiotics in these trials. Systematic analysis showed that probiotics did not significantly affect the pancreatic infection rate (RR = 1.19, 95% CI = 0.74 to 1.93; P = 0.47), total infections (RR = 1.09, 95% CI = 0.80 to 1.48; P = 0.57), operation rate (RR = 1.42, 95% CI = 0.43 to 3.47; P = 0.71), length of hospital stay (MD = 2.45, 95% CI = −2.71 to 7.60; P = 0.35) or mortality (RR = 0.72, 95% CI = 0.42 to 1.45; P = 0.25).

Conclusions

Probiotics showed neither beneficial nor adverse effects on the clinical outcomes of patients with predicted SAP. However, significant heterogeneity was noted between the trials reviewed with regard to the type, dose and treatment duration of probiotics, which may have contributed to the heterogeneity of the clinical outcomes. The current data are not sufficient to draw a conclusion regarding the effects of probiotics on patients with predicted SAP. Carefully designed clinical trials are needed to validate the effects of particular probiotics given at specific dosages and for specific treatment durations.
Appendix
Available only for authorised users
Literature
1.
Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ: Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143: 1179-1187. e3 10.1053/j.gastro.2012.08.002PubMedCentralCrossRefPubMed
2.
UK Working Party on Acute Pancreatitis: UK guidelines for the management of acute pancreatitis. Gut 2005, 54: iii1-iii9.CrossRef
3.
Beger HG, Rau B, Isenmann R: Natural history of necrotizing pancreatitis. Pancreatology 2003, 3: 93-101.CrossRefPubMed
4.
Bradley EL 3rd, Dexter ND: Management of severe acute pancreatitis: a surgical odyssey. Ann Surg 2010, 251: 6-17. 10.1097/SLA.0b013e3181c72b79CrossRefPubMed
5.
Dervenis C, Smailis D, Hatzitheoklitos E: Bacterial translocation and its prevention in acute pancreatitis. J Hepatobiliary Pancreat Surg 2003, 10: 415-418. 10.1007/s00534-002-0727-5CrossRefPubMed
6.
Van Felius ID, Akkermans LM, Bosscha K, Verheem A, Harmsen W, Visser MR, Gooszen HG: Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis. Neurogastroenterol Motil 2003, 15: 267-276. 10.1046/j.1365-2982.2003.00410.xCrossRefPubMed
7.
van Minnen LP, Nieuwenhuijs VB, de Bruijn MT, Verheem A, Visser MR, van Dijk JE, Akkermans LM, Gooszen HG: Effects of subtotal colectomy on bacterial translocation during experimental acute pancreatitis. Pancreas 2006, 32: 110-114. 10.1097/01.mpa.0000191650.24796.89CrossRefPubMed
8.
van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, Smidt H, Visser MR, Rijkers GT, Gooszen HG, Akkermans LM: Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery 2007, 141: 470-480. 10.1016/j.surg.2006.10.007CrossRefPubMed
9.
Akyol S, Mas MR, Comert B, Ateskan Ü, Yasar M, Aydogan H, Deveci S, Akay C, Mas N, Yener N, Kocar IH: The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas 2003, 26: 363-367. 10.1097/00006676-200305000-00009CrossRefPubMed
10.
Muftuoglu MAT, Isikgor S, Tosun S, Saglam A: Effects of probiotics on the severity of experimental acute pancreatitis. Eur J Clin Nutr 2006, 60: 464-468. 10.1038/sj.ejcn.1602338CrossRefPubMed
11.
Karen M, Yuksel O, Akyürek N, Ofluoğlu E, Çağlar K, Şahin TT, Paşaoğlu H, Memiş L, Akyürek N, Bostanci H: Probiotic agent Saccharomyces boulardii reduces the incidence of lung injury in acute necrotizing pancreatitis induced rats. J Surg Res 2010, 160: 139-144. 10.1016/j.jss.2009.02.008CrossRefPubMed
12.
Shimizu K, Ogura H, Goto M, Asahara T, Nomoto K, Morotomi M, Matsushima A, Tasaki O, Fujita K, Hosotsubo H, Kuwagata Y, Tanaka H, Shimazu T, Sugimoto H: Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report. Dig Dis Sci 2009, 54: 1071-1078. 10.1007/s10620-008-0460-2CrossRefPubMed
13.
Giamarellos-Bourboulis EJ, Bengmark S, Kanellakopoulou K, Kotzampassi K: Pro- and synbiotics to control inflammation and infection in patients with multiple injuries. J Trauma 2009, 67: 815-821. 10.1097/TA.0b013e31819d979eCrossRefPubMed
14.
Knight DJ, Gardiner D, Banks A, Snape SE, Weston VC, Bengmark S, Girling KJ: Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial. Intensive Care Med 2009, 35: 854-861. 10.1007/s00134-008-1368-1CrossRefPubMed
15.
Frohmader TJ, Chaboyer WP, Robertson IK, Gowardman J: Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial. Am J Crit Care 2010, 19: e1-e11. 10.4037/ajcc2010976CrossRefPubMed
16.
Alberda C, Gramlich L, Meddings J, Field C, McCargar L, Kutsogiannis D, Fedorak R, Madsen K: Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2007, 85: 816-823.PubMed
17.
Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E: Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial. World J Surg 2006, 30: 1848-1855. 10.1007/s00268-005-0653-1CrossRefPubMed
18.
Barraud D, Bollaert PE, Gibot S: Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials. Chest 2013, 143: 646-655.PubMed
19.
Möndel M, Schroeder BO, Zimmermann K, Huber H, Nuding S, Beisner J, Fellermann K, Stange EF, Wehkamp J: Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009, 2: 166-172. 10.1038/mi.2008.77CrossRefPubMed
20.
Duquesne S, Petit V, Peduzzi J, Rebuffat S: Structural and functional diversity of microcins, gene-encoded antibacterial peptides from enterobacteria. J Mol Microbiol Biotechnol 2007, 13: 200-209. 10.1159/000104748CrossRefPubMed
21.
Rea MC, Clayton E, O’Connor PM, Shanahan F, Kiely B, Ross RP, Hill C: Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol 2007, 56: 940-946. 10.1099/jmm.0.47085-0CrossRefPubMed
22.
Kabeerdoss J, Devi RS, Mary RR, Prabhavathi D, Vidya R, Mechenro J, Mahendri NV, Pugazhendhi S, Ramakrishna BS: Effect of yoghurt containing Bifidobacterium lactis Bb12 on faecal excretion of secretory immunoglobulin A and human β-defensin 2 in healthy adult volunteers. Nutr J 2011, 10: 138. 10.1186/1475-2891-10-138PubMedCentralCrossRefPubMed
23.
Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG, the Dutch Acute Pancreatitis Study Group: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371: 651-659. 10.1016/S0140-6736(08)60207-XCrossRefPubMed
24.
Cui LH, Wang XH, Peng LH, Yu L, Yang YS: The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013, 25: 224-228.PubMed
25.
Li Y: Adjuvant therapy for probiotics in patients with severe acute pancreatitis: an analysis of 14 cases [in Chinese]. Shijie Huaren Xiaohua Zazhi 2007, 15: 302-304.
26.
Oláh A, Belágyi T, Issekutz A, Gamal ME, Bengmark S: Randomized clinical trial of specific Lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002, 89: 1103-1107. 10.1046/j.1365-2168.2002.02189.xCrossRefPubMed
27.
Oláh A, Belágyi T, Pótó L, Romics L Jr, Bengmark S: Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology 2007, 54: 590-594.PubMed
28.
Plaudis H, Pupelis G, Zeiza K, Boka V: Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study. Acta Chir Belg 2012, 112: 131-138.PubMed
29.
Working Group IAP/APA Acute Pancreatitis Guidelines: IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology 2013, 13: e1-e15.CrossRef
30.
Toouli J, Brooke-Smith M, Bassi C, Carr-Locke D, Telford J, Freeny P, Imrie C, Tandon R: Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol 2002, 17: S15-S39.CrossRefPubMed
31.
Meier R, Beglinger C, Layer P, Gullo L, Keim V, Laugier R, Friess H, Schweitzer M, MacFie J, ESPEN Consensus Group: ESPEN guidelines on nutrition in acute pancreatitis. Clin Nutr 2002, 21: 173-183.CrossRefPubMed
32.
Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand JA, Skerrett SJ, Stapleton RD, Ware LB, Waldmann CS: Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004, 32: 2524-2536. 10.1097/01.CCM.0000148222.09869.92CrossRefPubMed
33.
Banks PA, Freeman ML: Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006, 101: 2379-2400. 10.1111/j.1572-0241.2006.00856.xCrossRefPubMed
34.
Takeda K, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, Kimura Y, Isaji S, Koizumi M, Otsuki M, Matsuno S: JPN Guidelines for the management of acute pancreatitis: medical management of acute pancreatitis. J Hepatobiliary Pancreat Surg 2006, 13: 42-47. 10.1007/s00534-005-1050-8PubMedCentralCrossRefPubMed
35.
Otsuki M, Hirota M, Arata S, Koizumi M, Kawa S, Kamisawa T, Takeda K, Mayumi T, Kitagawa M, Ito T, Inui K, Shimosegawa T, Tanaka S, Kataoka K, Saisho H, Okazaki K, Kuroda Y, Sawabu N, Takeyama Y, the Research Committee of Intractable Diseases of the Pancreas: Consensus of primary care in acute pancreatitis in Japan. World J Gastroenterol 2006, 12: 3314-3323.PubMedCentralPubMed
36.
American Gastroenterological Association Institute (AGA) on “Management of Acute Pancreatitis” Clinical Practice and Economics Committee; AGA Institute Governing Board: AGA Institute Medical Position Statement on Acute Pancreatitis. Gastroenterology 2007, 132: 2019-2021. 10.1053/j.gastro.2007.03.066CrossRef
37.
Pezzilli R, Uomo G, Zerbi A, Gabbrielli A, Frulloni L, De Rai P, Delle Fave G, Di Carlo V, Italian Association for the Study of the Pancreas and ProInf AISP (Computerized Project on Acute Pancreatitis) Study Group: Diagnosis and treatment of acute pancreatitis: the position statement of the Italian Association for the Study of the Pancreas. Dig Liver Dis 2008, 40: 803-808. 10.1016/j.dld.2008.02.019CrossRefPubMed
38.
Mirtallo JM, Forbes A, McClave SA, Jensen GL, Waitzberg DL, Davies AR, International Consensus Guideline Committee Pancreatitis Task Force: International consensus guidelines for nutrition therapy in pancreatitis. JPEN J Parenter Enteral Nutr 2012, 36: 284-291. 10.1177/0148607112440823CrossRefPubMed
39.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4CrossRefPubMed
40.
Ioannidis JP, Trikalinos TA: The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007, 176: 1091-1096. 10.1503/cmaj.060410PubMedCentralCrossRefPubMed
41.
Sun S, Yang K, He X, Tian J, Ma B, Jiang L: Probiotics in patients with severe acute pancreatitis: a meta-analysis. Langenbecks Arch Surg 2009, 394: 171-177. 10.1007/s00423-008-0379-2CrossRefPubMed
42.
Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C: Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 2011, 60: 1050-1059. 10.1136/gut.2010.232918CrossRefPubMed
43.
Meijerink M, van Hemert S, Taverne N, Wels M, de Vos P, Bron PA, Savelkoul HF, van Bilsen J, Kleerebezem M, Wells JM: Identification of genetic loci in Lactobacillus plantarum that modulate the immune response of dendritic cells using comparative genome hybridization. PLoS One 2010, 5: e10632. 10.1371/journal.pone.0010632PubMedCentralCrossRefPubMed
44.
Klarin B, Molin G, Jeppsson B, Larsson A: Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care 2008, 12: R136. 10.1186/cc7109PubMedCentralCrossRefPubMed
45.
McNaught CE, Woodcock NP, Anderson ADG, MacFie J: A prospective randomised trial of probiotics in critically ill patients. Clin Nutr 2005, 24: 211-219. 10.1016/j.clnu.2004.08.008CrossRefPubMed
46.
Oudhuis GJ, Bergmans DC, Dormans T, Zwaveling JH, Kessels A, Prins MH, Stobberingh EE, Verbon A: Probiotics versus antibiotic decontamination of the digestive tract: infection and mortality. Intensive Care Med 2011, 37: 110-117. 10.1007/s00134-010-2002-6PubMedCentralCrossRefPubMed
47.
Rayes N, Hansen S, Seehofer D, Müller AR, Serke S, Bengmark S, Neuhaus P: Early enteral supply of fiber and lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition 2002, 18: 609-615. 10.1016/S0899-9007(02)00811-0CrossRefPubMed
48.
Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, Bengmark S, Neuhaus P: Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation—a randomized, double-blind trial. Am J Transplant 2005, 5: 125-130. 10.1111/j.1600-6143.2004.00649.xCrossRefPubMed
49.
Spindler-Vesel A, Bengmark S, Vovk I, Cerovic O, Kompan L: Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enteral Nutr 2007, 31: 119-126. 10.1177/0148607107031002119CrossRefPubMed
50.
Tan M, Zhu JC, Du J, Zhang LM, Yin HH: Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: a prospective randomized pilot study. Crit Care 2011, 15: R290. 10.1186/cc10579PubMedCentralCrossRefPubMed
51.
Jain PK, McNaught CE, Anderson ADG, MacFie J, Mitchell CJ: Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus , Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Clin Nutr 2004, 23: 467-475. 10.1016/j.clnu.2003.12.002CrossRefPubMed
52.
Barraud D, Blard C, Hein F, Marçon O, Cravoisy A, Nace L, Alla F, Bollaert PE, Gibot S: Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med 2010, 36: 1540-1547. 10.1007/s00134-010-1927-0CrossRefPubMed
53.
Wen K, Li G, Bui T, Liu F, Li Y, Kocher J, Lin L, Yang X, Yuan L: High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs. Vaccine 2012, 30: 1198-1207. 10.1016/j.vaccine.2011.11.107PubMedCentralCrossRefPubMed
54.
Boyanova L, Mitov I: Coadministration of probiotics with antibiotics: Why, when and for how long? Expert Rev Anti Infect Ther 2012, 10: 407-409. 10.1586/eri.12.24CrossRefPubMed
55.
Sharma B, Srivastava S, Singh N, Sachdev V, Kapur S, Saraya A: Role of probiotics on gut permeability and endotoxemia in patients with acute pancreatitis: a double-blind randomized controlled trial. J Clin Gastroenterol 2011, 45: 442-448. 10.1097/MCG.0b013e318201f9e2CrossRefPubMed
56.
Besselink MGH, van Santvoort HC, van der Heijden GJMG, Buskens E, Gooszen HG: New randomized trial of probiotics in pancreatitis needed? Caution advised. Langenbecks Arch Surg 2009, 394: 191-194. 10.1007/s00423-008-0419-yCrossRefPubMed
57.
Capurso G, Marignani M, Piciucchi M, Merola E, Delle Fave G: Probiotics and severe acute pancreatitis [Addendum]. J Clin Gastroenterol 2008, 42: S152-S153.CrossRefPubMed
58.
Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GL, Van Buren CT, Rothkopf MM, Daly JM, Adelsberg BR: Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995, 23: 436-449. 10.1097/00003246-199503000-00006CrossRefPubMed
59.
Montejo JC, Zarazaga A, López-Martínez J, Urrútia G, Roqué M, Blesa AL, Celaya S, Conejero R, Galbán C, García de Lorenzo A, Grau T, Mesejo A, Ortiz-Leyba C, Planas M, Ordóñez J, Jiménez FJ, for the Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC), Spain: Immunonutrition in the intensive care unit: a systematic review and consensus statement. Clin Nutr 2003, 22: 221-233. 10.1016/S0261-5614(03)00007-4CrossRefPubMed
60.
Wilhelm SM, Kale-Pradhan PB: Combination of arginine and ω-3 fatty acids enteral nutrition in critically ill and surgical patients: a meta-analysis. Expert Rev Clin Pharmacol 2010, 3: 459-469. 10.1586/ecp.10.29CrossRefPubMed
Metadata
Title
Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials
Authors
Shanmiao Gou
Zhiyong Yang
Tao Liu
Heshui Wu
Chunyou Wang
Publication date
01-04-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13809

Other articles of this Issue 2/2014

Critical Care 2/2014 Go to the issue

Letter

Choosing the correct metrics for glucose control

Research

Risk stratification and prognostic performance of the predisposition, infection, response, and organ dysfunction (PIRO) scoring system in septic patients in the emergency department: a cohort study

Commentary

The dysfunctional host response to influenza A H7N9: a potential treatment option?

Commentary

Elevated malondialdehyde levels in sepsis - something to 'stress' about?

Commentary

Management of Pseudomonas aeruginosa pneumonia: one size does not fit all

Letter

Severity of post-cardiac surgery acute kidney injury and long-term mortality: is chronic kidney disease the missing link?